Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash from Operations (2018 - 2025)

Historic Cash from Operations for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $69.6 million.

  • TransMedics' Cash from Operations rose 91462.74% to $69.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.0 million, marking a year-over-year increase of 37534.99%. This contributed to the annual value of $48.8 million for FY2024, which is 47460.09% up from last year.
  • According to the latest figures from Q3 2025, TransMedics' Cash from Operations is $69.6 million, which was up 91462.74% from $91.6 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Cash from Operations peaked at $91.6 million during Q2 2025, and registered a low of -$18.4 million during Q1 2022.
  • Over the past 5 years, TransMedics' median Cash from Operations value was -$5.5 million (recorded in 2021), while the average stood at $6.3 million.
  • In the last 5 years, TransMedics' Cash from Operations plummeted by 15110.5% in 2022 and then soared by 91462.74% in 2025.
  • Quarter analysis of 5 years shows TransMedics' Cash from Operations stood at -$6.6 million in 2021, then surged by 39.31% to -$4.0 million in 2022, then surged by 305.8% to $8.3 million in 2023, then surged by 136.79% to $19.7 million in 2024, then surged by 253.83% to $69.6 million in 2025.
  • Its Cash from Operations stands at $69.6 million for Q3 2025, versus $91.6 million for Q2 2025 and -$2.9 million for Q1 2025.